Blue Horizon FDA Warning Letter & Stem Cell and Exosome Investigation

Federal regulators continue targeting marketing of unapproved regenerative therapies. On May 26, 2026, the FDA’s Center for Biologics Evaluation and Research issued a warning letter to Blue Horizon International, LLC of Hackensack, New Jersey. The letter addresses the company’s promotion of umbilical cord blood-derived stem cell therapy and Wharton’s jelly mesenchymal stem cell-derived exosome therapy for allogeneic use.

Contact a stem cell fraud lawyer to investigate your claim and to discuss taking legal action.

What the FDA Warning Letter to Blue Horizon International Says

Agency staff reviewed the website bluehorizonstemcells.com and cited extensive claims linking the products to treatment of multiple sclerosis, stroke recovery, spinal cord regeneration, osteoarthritis, rheumatoid arthritis, COPD, cirrhosis, Crohn’s disease, and diabetes.

The FDA determined both products qualify as unapproved new drugs and unlicensed biological products. Neither held an approved biologics license application nor an investigational new drug application.

The umbilical cord blood product also failed the homologous-use standard under human cell and tissue regulations, removing it from lighter oversight. The agency further found the products misbranded because they lacked adequate directions for safe lay use.

Blue Horizon International describes itself as a healthcare-management and research organization. Its materials state the cellular and exosome products remain investigational, lack FDA approval, and are not offered as medical treatment inside the United States.

The company points to research affiliations and frames its online content as educational. The FDA letter focuses solely on marketing claims and regulatory status; it does not evaluate clinical outcomes or allege patient harm.

Common Consumer Concerns in Stem Cell and Exosome Marketing Cases

Across the regenerative medicine sector, consumer complaints and lawsuits often center on a recurring set of issues. Marketing materials sometimes imply stem cell or exosome products can reverse aging or replace conventional care.

Other frequent concerns include incomplete disclosure of FDA status or high out-of-pocket costs for treatments that later yield limited results. These themes appear repeatedly in public records and litigation involving various clinics and suppliers. They are not accusations against Blue Horizon International or any affiliated entity.

The Lyon Firm has represented consumers in stem cell fraud and deceptive marketing cases for years. The Firm reviews situations that arise after FDA warning letters, examining whether advertising and sales practices matched available evidence and federal requirements.

Patients who spent significant sums on regenerative treatments and later questioned the representations made to them routinely seek counsel to evaluate contracts and medical records.

If you underwent stem cell or exosome therapy promoted for a serious condition and later learned the product lacked FDA approval, call us to review your claims. A free, confidential case review can help determine next steps. Contact The Lyon Firm at (513) 381-2333 or submit an online inquiry today.

FDA attention to unapproved regenerative products shows no sign of slowing. The Blue Horizon International warning letter joins a series of actions focused on website claims, homologous-use standards, and the absence of proper premarket pathways.

Anyone considering these therapies should demand clear answers about approval status, supporting clinical data, and proven alternatives before proceeding.